NV Bekaert SA (BEKAY)

CTI BioPharma Balance Sheet

Financials in millions EUR. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	462.72	504.38	631.69	728.1	677.27	940.42
Short-Term Investments	0.81	2.31	1.24	4.77	80.06	50.08
Trading Asset Securities	-	0.44	1.03	5.69	1.42	5.25
Cash & Short-Term Investments	463.54	507.13	633.96	738.56	758.74	995.74
Cash Growth	-5.21%	-20.00%	-14.16%	-2.66%	-23.80%	60.39%
Accounts Receivable	573.22	609.77	608.5	770.55	791.94	641.66
Other Receivables	129.78	133.47	102.37	153.38	159.58	104.34
Receivables	703	745.05	712.56	927.23	954.92	749.7
Inventory	762.45	833.99	788.51	1,143	1,121	683.48
Other Current Assets	76.03	65.4	59.88	45.36	36.69	36.68
Total Current Assets	2,005	2,152	2,195	2,854	2,872	2,466
Property, Plant & Equipment	1,226	1,345	1,253	1,369	1,386	1,324
Long-Term Investments	201.89	257.34	269.85	262.59	221.99	141.11
Goodwill	167.31	166.41	152.07	152.57	150.67	149.4
Other Intangible Assets	96.31	93.76	69.62	64.85	59.85	57.83
Long-Term Deferred Tax Assets	109.74	116.29	120.78	104.37	119.24	124.24
Other Long-Term Assets	88.12	31.4	21.02	21.91	30.04	25.53
Total Assets	3,895	4,162	4,081	4,829	4,839	4,288
Accounts Payable	613.47	668.11	632.95	921.11	1,062	668.42
Accrued Expenses	101.42	153.4	170.31	190.59	210.24	187.48
Current Portion of Long-Term Debt	292.94	284.85	230.81	480.79	219.22	622.11
Current Portion of Leases	-	24.26	21.57	20	20.22	19.75
Current Income Taxes Payable	67	71.53	57.78	66.18	86.13	53.54
Other Current Liabilities	68.16	46.48	34.78	45.55	37.86	37.99
Total Current Liabilities	1,143	1,249	1,148	1,724	1,636	1,589
Long-Term Debt	514.67	421.27	581.51	678.21	897.27	908.4
Long-Term Leases	-	74.95	65.14	57.2	56.43	60.76
Long-Term Deferred Tax Liabilities	34.42	31.32	35.62	44.02	52.06	38.34
Other Long-Term Liabilities	26.31	27.49	27.67	28.07	24.04	25.32
Total Liabilities	1,759	1,850	1,915	2,600	2,742	2,753
Common Stock	159.78	159.78	161.15	173.74	177.92	177.81
Additional Paid-In Capital	39.52	39.52	39.52	39.52	38.85	37.88
Retained Earnings	2,169	2,249	2,132	2,115	1,982	1,615
Treasury Stock	-	-81.5	-76.9	-139.31	-95.52	-106.15
Comprehensive Income & Other	-271.08	-108.95	-142.84	-96.45	-136.44	-276.45
Total Common Equity	2,097	2,258	2,113	2,093	1,967	1,448
Minority Interest	38.21	53.69	53.16	136.85	130.97	87.18
Shareholders' Equity	2,135	2,312	2,166	2,230	2,098	1,535
Total Liabilities & Equity	3,895	4,162	4,081	4,829	4,839	4,288
Total Debt	807.6	805.33	899.04	1,236	1,193	1,611
Net Cash (Debt)	-344.07	-298.2	-265.08	-497.64	-434.4	-615.27
Net Cash Per Share	-6.62	-5.68	-4.92	-8.78	-7.54	-9.59
Filing Date Shares Outstanding	51.4	52.05	52.59	54.65	57.31	56.6
Total Common Shares Outstanding	51.4	52.05	52.59	54.65	57.31	56.6
Working Capital	862.02	902.95	1,047	1,130	1,236	876.31
Book Value Per Share	40.80	43.38	40.17	38.29	34.32	25.58
Tangible Book Value	1,833	1,998	1,891	1,875	1,756	1,241
Tangible Book Value Per Share	35.67	38.38	35.96	34.32	30.65	21.92
Land	-	1,227	1,159	1,267	1,215	1,148
Machinery	-	3,176	3,012	3,157	3,068	2,882
Construction In Progress	-	208.77	180.43	184.11	151.09	84.02

Updated Feb 28, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.